Zobrazeno 1 - 10
of 527
pro vyhledávání: '"P. Omvik"'
Autor:
Elfrida H. Kvarstein, Mathias Frøyhaug, Mona S. Pettersen, Sara Carlsen, Andreas Ekberg, Jane Fjermestad-Noll, Dag A. Ulvestad, Elisabeth L. Gikling, Eirik Hjermann, Kenneth Lindberget, Siri Omvik, Ingeborg U-M. Eikenæs, Benjamin Hummelen, Katharina T. E. Morken, Theresa Wilberg, Geir A. F. Pedersen
Publikováno v:
Frontiers in Psychiatry, Vol 14 (2023)
ObjectiveEvidence-based personality disorder (PD) treatments are dominated by interventions targeting Borderline PD, although clinical populations characteristically include different PD features and severity. Personality functioning is a new concept
Externí odkaz:
https://doaj.org/article/6613f06822a64e248d361718ca3c5e6f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J. Forte, K. Beard, Willemse P, Brixko P, P. Leeuw, J C Petrie, Morris J, P. Miguel, J. Tuomilehto, Denis Clement, Feltkamp H, MacFarlane J, A. Schaepdryver, A. Koistinen, B. O. Williams, R. Harady, A. Nissinen, Pekka Puska, Robert Fagard, C. J. Bulpitt, P. Lewis, K. Meurer, W G O'Callaghan, John Webster, Marcus Bogaert, Henry Jf, R. Varis, Gastone Leonetti, Eoin O'Brien, Deruyttere M, P. Omvik, Kevin O'Malley, W. Birkenhager, Antoon Amery, Per Lund-Johansen, R Grauwels, L. Terzoli, J.F. Plaen, Mutsers A, Françoise Forette
Publikováno v:
Acta Medica Scandinavica. 214:119-140
792 hypertensive patients above the age of 60 have entered the double-blind multicentre trial of the European Working Party on High blood pressure in the Elderly (EWPHE). Half were treated with hydrochlorothiazide and triamterene and half were given
Autor:
Hans Wedel, F Fyhrquist, R Devereux, U de Faire, M S Nieminen, K Kristianson, Thomas Hedner, Björn Dahlöf, S Kjeldsen, L H Lindholm, S Oparil, H Ibsen, Stevo Julius, P Omvik, O Lederballe-Pedersen
Publikováno v:
American Journal of Hypertension. 10:705-713
The treatment of hypertension mainly with diuretics and beta blockers reduces cardiovascular mortality and morbidity, largely due to a decreased incidence of stroke, whereas the beneficial effects of antihypertensive therapy on the occurrence of coro
Publikováno v:
Journal of Hypertension. 13:1343-1351
To evaluate the blood pressure lowering efficacy as well as tolerability and safety of the angiotensin II antagonist losartan compared with that of the angiotensin converting enzyme inhibitor enalapril in patients with mild-to-moderate essential hype
Autor:
P. Omvik, P. Lund-Johansen
Publikováno v:
European Heart Journal. 13:281-286
Nineteen men (mean age 44 years) with essential hypertension, WHO stage I, were studied invasively at rest and during exercise. Blood pressure was recorded intra-arterially (brachial artery), cardiac output by dye dilution method and heart rate by el
Autor:
P. Lund-Johansen, P. Omvik
Publikováno v:
European Heart Journal. 11:543-551
The effects of long-term treatment with diltiazem on blood pressure, central haemodynamics and exercise endurance were studied in 16 men (mean age 52 years) with essential hypertension. Intra-arterial pressure and heart rate (HR) were monitored conti
Autor:
P. Omvik, P. Lund-Johansen
Publikováno v:
European Journal of Clinical Pharmacology. 38:S89-S95
A 20-year follow-up study of central hemodynamics in essential hypertension at rest and during exercise in 61 men with uncomplicated essential hypertension has clearly shown that hemodynamic disturbances depend on the age of the subjects and the seve
Publikováno v:
Managed care interface. 14(3)
A comparison of treatment costs and cost effectiveness was performed retrospectively by using patient-level data from a randomized, controlled, one-year clinical trial of amlodipine and enalapril in the treatment of mild-to-moderate hypertension. Uni
Autor:
S E, Kjeldsen, B, Dahlöf, R B, Devereux, S, Julius, U, de Faire, F, Fyhrquist, H, Ibsen, K, Kristianson, O, Lederballe-Pedersen, L H, Lindholm, M S, Nieminen, P, Omvik, S, Oparil, H, Wedel
Publikováno v:
American journal of hypertension. 13(8)
The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel-group study comparing the effects of losartan with those of atenolol on the reduction of cardiovascular complications in patients (